1. Basic Product Identification
Name: Deferasirox
Class: Iron Chelating Agent
ATC Code: V03AC03
Molecular Formula: C₂₁H₁₅N₃O₄
Molecular Weight: 373.37 g/mol
Appearance: White to yellowish crystalline powder
Solubility: Practically insoluble in water, soluble in DMSO/alkaline media
Key Characteristic: Oral once-daily iron chelator
2. Therapeutic Knowledge
Indication:
Chronic iron overload due to:
Blood transfusions (thalassemia, sickle cell anemia)
Non-transfusion-dependent thalassemia
Therapeutic Class: Chelating agent
Clinical Purpose:
Reduce iron toxicity in heart, liver, endocrine organs
???? Prevents organ damage from iron accumulation
3. Mechanism of Action (MOA)
Binds trivalent iron (Fe³⁺) with high affinity
Forms stable 1:2 or 2:1 drug–iron complexes
Promotes fecal excretion of iron
Does NOT affect other essential metals significantly at therapeutic doses
???? Outcome: reduction of total body iron load
4. Pharmacokinetics (ADME)
Absorption
Oral bioavailability: ~70% (variable)
Enhanced with fatty food
Distribution
Highly protein bound (~99%)
Metabolism
Liver: UGT1A1 and UGT1A3 glucuronidation
Minor CYP involvement
Excretion
Primarily fecal (~80%)
Urine (~8%)
Half-life
8–16 hours (dose dependent)
5. Dosage & Administration
Standard dosing
20 mg/kg once daily (initial)
Range: 10–40 mg/kg/day depending iron load
Forms
Dispersible tablets
Film-coated tablets (improved compliance)
Administration rules
Taken on empty stomach
Dispersed in water/juice for dispersible form
6. Formulation Knowledge
Dosage Forms
Oral dispersible tablets
Film-coated tablets
Key Excipients
Microcrystalline cellulose
Crospovidone (disintegration)
Povidone (binder)
Sodium lauryl sulfate (wetting agent)
Iron-free excipients critical (no contamination risk)
7. Raw Materials Knowledge
API: Deferasirox (chelating aromatic heterocycle)
Key raw materials:
Benzothiazole intermediates
Salicylic acid derivatives
Organic solvents (DMF, ethanol)
Critical concern:
Metal contamination control (Fe, Cu, Zn)
8. Manufacturing Process Knowledge
API Synthesis (high-level)
Heterocyclic condensation reactions
Formation of triazole-linked benzothiazole system
Purification via recrystallization
Strict metal-free environment required
Formulation Process
Wet or dry granulation
Low moisture processing (API sensitive)
Compression into dispersible tablets
Coating for taste masking & stability
9. Analytical & QC Knowledge
Key Tests
Assay (HPLC)
Related substances / degradation profile
Dissolution (critical for bioavailability)
Water content (Karl Fischer)
Metal impurity testing (ICP-MS)
Particle size distribution (API consistency)
Critical impurities
Oxidation products
Hydrolysis derivatives
Process-related intermediates
10. Regulatory Knowledge
Approved by FDA, EMA, WHO essential medicine list
Requires:
DMF for API
ANDA (US generics)
High regulatory scrutiny due to:
Narrow therapeutic window
Pediatric use in some cases
Stability per ICH guidelines required
11. Storage & Stability
Store at 20–25°C
Protect from:
Moisture
Light
Stable in dry form
Sensitive to hydrolysis under alkaline conditions
12. Packaging Knowledge
API:
Double polyethylene liner + fiber drum
Tablets:
Alu-Alu blister (moisture protection)
Dispersible tablets:
High barrier packaging critical
13. Safety & Toxicology
Common side effects:
GI upset (nausea, diarrhea)
Increased creatinine (renal monitoring needed)
Liver enzyme elevation
Serious risks:
Renal failure (rare)
Hepatic toxicity
Skin rash
Contraindication:
Severe renal impairment
14. Market & Commercial Knowledge
Global demand driven by:
Thalassemia prevalence (India, Middle East)
Blood transfusion programs
Key brands:
Exjade
Jadenu
Market trend:
Shift to once-daily tablets from dispersible forms
High generic penetration globally
15. Intellectual Property (IP)
Original developer: Novartis
Patent expiry: largely expired in many regions
Remaining IP:
Formulation patents (tablet forms)
Controlled-release improvements
Market now:
Highly competitive generics
16. Environmental & EHS Knowledge
Low environmental toxicity
Manufacturing concerns:
Solvent emissions control
Metal contamination waste management
EHS requirement:
Heavy metal-free zones in production
17. Export Documentation Knowledge
COA (batch-wise)
MSDS/SDS
GMP certificate
DMF / CEP (EU)
Stability data (Zone II–IV)
Metal impurity declaration (critical for deferasirox)
18. Business Development Knowledge
High-volume markets:
India
Southeast Asia
Africa (thalassemia burden)
Strategy:
Cost-effective generic API supply
Pediatric dispersible tablet formulations
Growth areas:
Fixed-dose combinations (future potential)
Improved bioavailability formulations
19. Advanced Technical Knowledge
Metal chelation chemistry optimization
pH-dependent solubility profile critical
API requires ultra-low metal contamination environment
Bioequivalence challenges in dispersible vs film-coated forms
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
Impurity prediction modeling
Process optimization (reaction yield improvement)
Supply chain forecasting for hematology drugs
Digital QA:
LIMS for impurity tracking
PAT for granulation consistency
Smart manufacturing:
Metal contamination sensors in real-time
21. Sales Team Product Knowledge Checklist
Sales must understand:
Iron overload disease basics
Dose based on body weight (mg/kg)
Importance of compliance (lifelong therapy)
Difference between brands (Exjade vs Jadenu)
Safety monitoring (kidney/liver tests)
Key objection handling:
GI side effects → explain titration
Cost deferasirox API Exporter from Kabul → emphasize long-term organ protection
22. Most Important Technical Documents
DMF (API dossier)
ANDA filings
Bioequivalence studies
Stability reports (ICH)
Dissolution profile similarity
Metal impurity validation reports
Process validation reports
Cleaning validation (metal-free systems)
23. Ultimate Pharma Product Mastery Summary
Deferasirox is:
A life-saving oral iron chelator
Essential in transfusion-dependent anemia care
Technically challenging due to:
Metal contamination sensitivity
Bioequivalence requirements
Safety monitoring requirements
???? Competitive success depends on:
Ultra-pure API manufacturing
Consistent dissolution profile
Cost-effective formulation strategy
Strong regulatory compliance